Mike joined NEA in 2002 as a Partner. He specializes in healthcare investments focusing on biotechnology and pharmaceutical sectors. Current board memberships include Amicus Therapeutics (NASDAQ: FOLD), Intarcia, CellGate, Novacea, Hyperion and Macroflux. Mike is also actively involved with 23andMe, Trine Pharmaceuticals, Liquidia and Vitae Pharmaceuticals. As well, Mike is a member of the Life Sciences Advisory Board for ...
more
Mike joined NEA in 2002 as a Partner. He specializes in healthcare investments focusing on biotechnology and pharmaceutical sectors. Current board memberships include Amicus Therapeutics (NASDAQ: FOLD), Intarcia, CellGate, Novacea, Hyperion and Macroflux. Mike is also actively involved with 23andMe, Trine Pharmaceuticals, Liquidia and Vitae Pharmaceuticals. As well, Mike is a member of the Life Sciences Advisory Board for Silicon Valley Bank. Prior to joining NEA, Mike was most recently Senior Vice President, Therapeutics and General Manager, of the Renal Division at Genzyme Corporation. Prior to that, Mike was Vice President of Business Development for the Therapeutics Division, responsible for the identification and in-licensing of new therapeutic product opportunities. He gained extensive international experience while building a commercial operation in Latin America for the Therapeutics and Surgical Products groups for the company. Mike was also Product Manager for Ceredase and was instrumental in the worldwide launch of Cerezyme, Genzyme’s $1 Billion therapies for Gaucher Disease. Mike also spent two years with Genzyme’s Diagnostic products and services division. Previous to Genzyme, Mike held sales and marketing positions at Repligen and Bristol-Myers. Mike received his BA from DePauw University.
less
